MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$17,894K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Accrued expenses and other liabi...
Operating lease liabilities
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Deferred revenue
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,191
-19,875
-21,664
-52,619
Stock-based compensation expense
2,550
2,383
2,241
2,733
Depreciation and amortization expense
230
238
802
852
Loss on disposal of property and equipment
-
-
-31
-
Gain on lease modification
-
-
1,632
-
Impairment of long-lived assets
-
-
5,914
0
Noncash lease expense
541
561
543
696
Accretion of discount on marketable securities
618
388
306
356
Prepaid expenses and other current assets
-719
91
501
-1,339
Accounts payable
-69
-990
1,054
-110
Accrued expenses and other liabilities
1,061
-4,458
1,435
1,157
Operating lease liabilities
1,005
621
-941
-1,169
Deferred revenue
-16,072
-3,267
-9,247
-8,153
Net cash used in operating activities
-17,844
-25,266
-22,271
-18,860
Purchases of property and equipment
50
0
0
0
Purchases of marketable securities
37,083
66,938
33,981
4,002
Proceeds from maturities of marketable securities
34,166
49,219
47,213
39,575
Net cash provided by (used in) investing activities
-2,967
-17,719
13,232
35,573
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-Prefunded Warrants
-
-
0
-
Proceeds from offerings of common stock, pre-funded warrants, and series warrants net of underwriting discounts and commissions
0
49,999
-
0
Payments of public offering costs
31
316
0
0
Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan
9
89
41
49
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-At Market Offering
-
-
540
-
Net cash provided by financing activities
-22
49,772
581
49
Net increase (decrease) in cash, cash equivalents and restricted cash
-20,833
6,787
-8,458
16,762
Cash, cash equivalents and restricted cash at beginning of period
90,913
84,126
92,584
57,162
Cash, cash equivalents and restricted cash at end of period
70,080
-
-
-
Cash paid for taxes
2
-
-
-
Cash and cash equivalents
68,080
-
-
-
Restricted cash
2,000
-
-
-
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
70,080
90,913
84,126
92,584
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash, cash...
-$20,833K
(-211.65%↓ Y/Y)
Stock-based compensation
expense
$2,550K
(-53.00%↓ Y/Y)
Accrued expenses and
other liabilities
$1,061K
(373.45%↑ Y/Y)
Operating lease
liabilities
$1,005K
(121.69%↑ Y/Y)
Prepaid expenses and
other current assets
-$719K
(63.85%↑ Y/Y)
Noncash lease expense
$541K
(-81.77%↓ Y/Y)
Depreciation and
amortization expense
$230K
(-86.29%↓ Y/Y)
Proceeds from maturities
of marketable...
$34,166K
(-78.18%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$9K
(-97.71%↓ Y/Y)
Net cash used in
operating activities
-$17,844K
(60.32%↑ Y/Y)
Net cash provided by
(used in) investing...
-$2,967K
(-104.69%↓ Y/Y)
Net cash provided by
financing activities
-$22K
(-105.60%↓ Y/Y)
Canceled cashflow
$6,106K
Canceled cashflow
$34,166K
Canceled cashflow
$9K
Deferred revenue
-$16,072K
(-18.97%↓ Y/Y)
Net loss
-$7,191K
Purchases of marketable
securities
$37,083K
(-60.24%↓ Y/Y)
Payments of public
offering costs
$31K
Accretion of discount on
marketable securities
$618K
(-51.11%↓ Y/Y)
Accounts payable
-$69K
(85.10%↑ Y/Y)
Purchases of property and
equipment
$50K
(0.00%↑ Y/Y)
Buy us a coffee
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)